|
Variability in patient responsiveness to clopidogrel among 544
individuals.
Traditional platelet aggregometry is
timeconsuming, technically challenging and expensive. Platelet
baseline function for aggregometry also requires drug withdrawal,
with its significant associated risks. The two channel system
allows for measurement of percent inhibition in patients currently
taking thienopyridines. This eliminates the need for drug
withdrawal and obviates the need for testing the patient twice,
providing a safer and more costeffective approach to monitoring
platelet inhibition. For patients on chronic antiplatelet therapy,
target target platelet inhibition with plavix of
platelet target platelet inhibition with plavix are 50%.
Patients with adequate platelet inhibition have an increased risk
of bleeding, and withdrawal of clopidogrel is recommended five
days prior to surgery. Invert tubes several times to avoid
clotting. Verify that the expiration date of the tubes is
acceptable. Specimens need to arrive at the laboratory within 3
hours of collection. Antiplatelet therapy in neuroendovascular
therapeutics.
These compounds include the thienopyridine
class of drugs, including clopidogrel and ticlopidine. For
patients taking both aspirin and a thienopyridine, the two tests
may be ordered simultaneously. This trend has led to the emergence
of the new clinical entity of clopidogrel resistance. Research has
revealed that 5% to 30% of patients do not respond adequately to
standard doses of clopidogrel. The target platelet inhibition with
plavix of clopidogrel resistance can be catastrophic,
necessitating a means for monitoring antiplatelet therapy.
|
